| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 5703496 | Archivos de la Sociedad Española de Oftalmología | 2017 | 8 Pages |
Abstract
A PRN dosing strategy with intravitreal ranibizumab for neovascular AMD may not be efficient in preserving and/or recovering VA in the long-term, due to a cumulative irreversible VA loss.
Related Topics
Health Sciences
Medicine and Dentistry
Ophthalmology
Authors
R. Gallego-Pinazo, R. Dolz-Marco, M. Andreu-Fenoll, J. Farrés, L. Monclús,